Abiopharma

🔍 Myles David C. (Executive)

Company: Olema Pharmaceuticals, Inc. (OLMA)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Sold 10,000 shares of Common Stock at $28.34 per share (Direct)
  Date: 2026-01-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 144,846.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 50,000 shares of Common Stock at $4.87 per share (Direct)
  Date: 2026-01-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 592,761.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 49,800 shares of Common Stock at $27.6 per share (Direct)
  Date: 2026-01-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 542,961.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 200 shares of Common Stock at $28.49 per share (Direct)
  Date: 2026-01-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 542,761.00 | transaction_form_type: 4
• Acquired 50,000 shares of Common Stock at $4.87 per share (Direct)
  Date: 2026-01-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 592,761.00 | transaction_form_type: 4
• Sold 14,997 shares of Common Stock at $28.6 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 577,764.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 35,003 shares of Common Stock at $28.99 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 542,761.00 | transaction_form_type: 4 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 12,831.00 | Footnotes: F7
• Sold 50,000 shares of Stock Option (Right to Buy) at $4.87 per share (Derivative)
  Date: 2026-01-13 | Code: M | Expires: 2033-01-31 | equity_swap_involved: 0 | shares_owned_after: 100,000.00 | transaction_form_type: 4 | Footnotes: F8
• Sold 50,000 shares of Stock Option (Right to Buy) at $4.87 per share (Derivative)
  Date: 2026-01-14 | Code: M | Expires: 2033-01-31 | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F9

Footnotes:

• F1: The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
• F2: The shares are held by Myles Properties Inc., of which the Reporting Person is President.
• F3: On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4.
• F4: The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
• F5: The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
• F6: The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
• F7: The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
• F8: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
• F9: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.